IMEMR
EMRO
66.92
Index Copernicus
ICICICICICICICIC
Volume 2, Issue 1 (2021)
J Clinic Care Skill 2021, 2(1): 1-8 |
Back to browse issues page
Article Type:
History
Received: 2019/11/16 | Accepted: 2020/08/9 | Published: 2021/01/20
Received: 2019/11/16 | Accepted: 2020/08/9 | Published: 2021/01/20
How to cite this article
Nedaei K, Salehi Z, Alipoor B, Jafarzadeh M, Aljamal M, Zoladl M. A Review of Outstanding Retinoblastoma Researches on RB1 Genes: Focus on Treatment by Non-ionizing and Ionizing Radiation. J Clinic Care Skill 2021; 2 (1) :1-8
URL: http://jccs.yums.ac.ir/article-1-76-en.html
URL: http://jccs.yums.ac.ir/article-1-76-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- Department of Radiation Sciences, School of Paramedical Sciences, Yasuj University of Medical Sciences, Yasuj, Iran
2- Department of Laboratory Sciences, School of Paramedical Sciences, Yasuj University of Medical Sciences, Yasuj, Iran
3- Department of Medical Radiation, Faculty of Allied Medical Sciences, Arab American University, Jenin, Palestine ,mohammad.aljamal@aaup.edu
4- Social Determinants of Health Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
2- Department of Laboratory Sciences, School of Paramedical Sciences, Yasuj University of Medical Sciences, Yasuj, Iran
3- Department of Medical Radiation, Faculty of Allied Medical Sciences, Arab American University, Jenin, Palestine ,
4- Social Determinants of Health Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
Abstract (2115 Views)
Introduction: Retinoblastoma (RB) is a malignant retinal tumor, which affects infants and children. This cancer happens through a mutation in the retinoblastoma tumor suppressor genes (RB1). Inactivation of RB1 has been observed in more than 97% of all retinoblastoma patients with mutations. In recent years, RB treatment has developed significantly. RB's treatment methods can be one or a combination of the following treatments, including chemotherapy, non-ionizing, or ionizing radiation. This article aimed to review each treatment method's role and its effectiveness in the treatment of RB. Several articles from 2004 to 2020 were reviewed in PubMed, Web of Science, Google Scholar, and Scopus, based on the RB treatments, of which 73 were selected for this study.
Conclusion: It can be concluded that ionizing and non-ionizing radiation play an important role in treating retinoblastoma. It was also shown that a combination of radiation treatments is more effective than traditional therapeutic methods.
Ionized and non-Ionized radiations can be used as an effective treatment to cure retinoblastoma.
Conclusion: It can be concluded that ionizing and non-ionizing radiation play an important role in treating retinoblastoma. It was also shown that a combination of radiation treatments is more effective than traditional therapeutic methods.
Ionized and non-Ionized radiations can be used as an effective treatment to cure retinoblastoma.
Keywords:
Retinoblastoma [MeSH], Treatment [MeSH], RB1 Gene [MeSH], Ionizing Radiation [MeSH], Non-Ionizing Radiation [MeSH]
References
1. Carvalho INSR, Reis AH, dos Santos ACE, Vargas FR. A polymorphism in mir-34b/c as a potential biomarker for early onset of hereditary retinoblastoma. Cancer Biomark Sect A Dis Mark. 2017;18(3):313-7. [Link] [DOI:10.3233/CBM-160248]
2. Cao Q, Wang Y, Song X, Yang W. Association between MDM2 rs2279744, MDM2 rs937283, and p21 rs1801270 polymorphisms and retinoblastoma susceptibility. Medicine (Baltimore). 2018;97(49):e13547. [Link] [DOI:10.1097/MD.0000000000013547]
3. AlAli A, Kletke S, Gallie B, Lam WC. Retinoblastoma for pediatric ophthalmologists. A Asia Pac J Ophthalmol (Phila). 2018;7(3):160-8. [Link]
4. Aerts I, Lumbroso-Le Rouic L, Gauthier-Villars M, Brisse H, Doz F. Retinoblastoma update. Arch Pediatr. 2016;23(1):112-6. [French] [Link] [DOI:10.1016/j.arcped.2015.09.025]
5. de Carvalho INSR, de Freitas RM, Vargas FR. Translating microRNAs into biomarkers: What is new for pediatric cancer?. Med Oncol. 2016;33(5):49. [Link] [DOI:10.1007/s12032-016-0766-4]
6. Simon GR, Baker C, Barden GA, Brown OW, Hardin A, Lessin HR, et al. 2014 recommendations for pediatric preventive health care. Pediatrics. 2014;133(3):568-70. [Link] [DOI:10.1542/peds.2013-4096]
7. Houdayer C, Gauthier-Villars M, Laugé A, Pagès-Berhouet S, Dehainault C, Caux-Moncoutier V, et al. Comprehensive screening for constitutional RB1 mutations by DHPLC and QMPSF. Hum Mutat. 2004;23(2):193-202. [Link] [DOI:10.1002/humu.10303]
8. Li WL, Buckley J, Sanchez-Lara PA, Maglinte DT, Viduetsky L, Tatarinova TV, et al. A rapid and sensitive next-generation sequencing method to detect RB1 mutations improves care for retinoblastoma patients and their families. The J Mol Diagn. 2016;18(4):480-93. [Link] [DOI:10.1016/j.jmoldx.2016.02.006]
9. Singh HP, Wang S, Stachelek K, Lee S, Reid MW, Thornton ME, et al. Developmental stage-specific proliferation and retinoblastoma genesis in RB-deficient human but not mouse cone precursors. Proc Nat Acad Sci U S A. 2018;115(40):E9391-e400. [Link] [DOI:10.1073/pnas.1808903115]
10. Wong JR, Tucker MA, Kleinerman RA, Devesa SS. Retinoblastoma incidence patterns in the US Surveillance, Epidemiology, and End Results program. JAMA Ophthalmol. 2014;132(4):478-83. [Link] [DOI:10.1001/jamaophthalmol.2013.8001]
11. Truong B, Green AL, Friedrich P, Ribeiro KB, RodriguezGalindo C. Ethnic, racial, and socioeconomic disparities in retinoblastoma. JAMA Pediatr. 2015;169(12):1096-104. [Link] [DOI:10.1001/jamapediatrics.2015.2360]
12. Andreoli MT, Chau FY, Shapiro MJ, Leiderman YI. Epidemiological trends in 1452 cases of retinoblastoma from the Surveillance, Epidemiology, and End Results (SEER) registry. Can J Ophthalmol. 2017;52(6):592-8. [Link] [DOI:10.1016/j.jcjo.2017.05.012]
13. Friedrich P, Itriago E, Rodriguez-Galindo C, Ribeiro K. Racial and ethnic disparities in the incidence of pediatric extracranial embryonal tumors. J Nat Cancer Inst. 2017;109(10). [Link] [DOI:10.1093/jnci/djx050]
14. Hossain MS, Begum M, Mian MM, Ferdous S, Kabir S, Sarker HK, et al. Epidemiology of childhood and adolescent cancer in Bangladesh, 2001-2014. BMC Cancer. 2016;16:104. [Link] [DOI:10.1186/s12885-016-2161-0]
15. Jardel P, Caujolle JP, Gastaud L, Maschi C, Sauerwein W, Thariat J. Malignant tumours of the eye: Epidemiology, diagnostic methods and radiotherapy. Cancer Radiother. 2015;19(8):762-74. [French] [Link] [DOI:10.1016/j.canrad.2015.04.008]
16. Musselman JRB, Spector LG, Krailo MD, Reaman GH, Linabery AM, Poynter JN, et al. The Children's Oncology Group Childhood Cancer Research Network (CCRN): Case catchment in the United States. Cancer. 2014;120(19):3007-15. [Link] [DOI:10.1002/cncr.28813]
17. Temming P, Viehmann A, Biewald E, Lohmann DR. Sporadic unilateral retinoblastoma or first sign of bilateral disease?. Br J Ophthalmol. 2013;97(4):475-80. [Link] [DOI:10.1136/bjophthalmol-2012-302666]
18. de Paula Silva N, de Souza Reis R, Garcia Cunha R, Pinto Oliveira JF, de Oliveira Santos M, Pombo-de-Oliveira MS, et al. Maternal and birth characteristics and childhood embryonal solid tumors: A population-based report from brazil. PloS One. 2016;11(10):e0164398. [Link] [DOI:10.1371/journal.pone.0164398]
19. Heck JE, Contreras ZA, Park AS, Davidson TB, Cockburn M, Ritz B. Smoking in pregnancy and risk of cancer among young children: A population-based study. Int J Cancer. 2016;139(3):613-6. [Link] [DOI:10.1002/ijc.30111]
20. Gao J, Zeng J, Guo B, He W, Chen J, Lu F, et al. Clinical presentation and treatment outcome of retinoblastoma in children of South Western China. Medicine (Baltimore). 2016;95(42):e5204. [Link] [DOI:10.1097/MD.0000000000005204]
21. Azary S, Ganguly A, Bunin GR, Lombardi C, Park AS, Ritz B, et al. Sporadic retinoblastoma and parental smoking and alcohol consumption before and after conception: A report from the children's oncology group. PloS One. 2016;11(3):e0151728. [Link] [DOI:10.1371/journal.pone.0151728]
22. Jin L, Zhang W, Pan H, Li T, Liu B, Zhao J, et al. Retrospective investigation of retinoblastoma in Chinese patients. Oncotarget. 2017;8(65):108492-7. [Link] [DOI:10.18632/oncotarget.18174]
23. Kitajima S, Takahashi C. Intersection of retinoblastoma tumor suppressor function, stem cells, metabolism, and inflammation. Cancer Sci. 2017;108(9):1726-31. [Link] [DOI:10.1111/cas.13312]
24. Lohmann D. Retinoblastoma. In: Ahmad SI. editors. Diseases of DNA repair. Advances in experimental medicine and biology. New York: Springer; 2010. [Link] [DOI:10.1007/978-1-4419-6448-9_21]
25. Abramson DH, Shields CL, Munier FL, Chantada GL. Treatment of retinoblastoma in 2015: Agreement and disagreement. JAMA Ophthalmol. 2015;133(11):1341-7. [Link] [DOI:10.1001/jamaophthalmol.2015.3108]
26. Yanagisawa T. Systemic chemotherapy as a new conservative treatment for intraocular retinoblastoma. Int J Clin Oncol. 2004;9(1):13-24. [Link] [DOI:10.1007/s10147-003-0368-y]
27. Wilson MW, Haik BG, Billups CA, Rodriguez-Galindo C. Incidence of new tumor formation in patients with hereditary retinoblastoma treated with primary systemic chemotherapy: Is there a preventive effect?. Ophthalmology. 2007;114(11):2077-82. [Link] [DOI:10.1016/j.ophtha.2007.03.015]
28. Zhao J, Feng ZX, Wei M, Liu G, Solarte CE, Li B, et al. impact of systemic chemotherapy and delayed enucleation on survival of children with advanced intraocular retinoblastoma. Ophthalmol Retina. 2020;4(6):630-9. [Link] [DOI:10.1016/j.oret.2020.02.015]
29. Biewald E, Holdt M, Bornfeld N. New therapeutic strategies for retinoblastoma: Non-systemic chemotherapy. Ophthalmologe. 2014;111(4):379-82. [German] [Link] [DOI:10.1007/s00347-014-3038-8]
30. Temming P, Arendt M, Viehmann A, Eisele L, Le Guin CHD, Schundeln MM, et al. Incidence of second cancers after radiotherapy and systemic chemotherapy in heritable retinoblastoma survivors: A report from the German reference center. Pediatr Blood Cancer. 2017;64(1):71-80. [Link] [DOI:10.1002/pbc.26193]
31. Shields CL, Mashayekhi A, Au AK, Czyz C, Leahey A, Meadows AT, et al. The international classification of retinoblastoma predicts chemoreduction success. Ophthalmology. 2006;113(12):2276-80. [Link] [DOI:10.1016/j.ophtha.2006.06.018]
32. Shields CL, Ramasubramanian A, Thangappan A, Hartzell K, Leahey A, Meadows AT, et al. Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus lowdose external radiotherapy in 76 eyes. Ophthalmology. 2009;116(3):544-551.e1. [Link] [DOI:10.1016/j.ophtha.2008.10.014]
33. Zage PE, Reitman AJ, Seshadri R, Weinstein JL, Mets MB, Zeid JL, et al. Outcomes of a two-drug chemotherapy regimen for intraocular retinoblastoma. Pediatr Blood Cancer. 2008;50(3):567-72. [Link] [DOI:10.1002/pbc.21301]
34. Gombos DS, Hungerford J, Abramson DH, Kingston J, Chantada G, Dunkel IJ, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: Is chemotherapy a factor?. Ophthalmology. 2007;114(7):1378-83. [Link] [DOI:10.1016/j.ophtha.2007.03.074]
35. Tuncer S, Sencer S, Kebudi R, Tanyildiz B, Cebeci Z, Aydin K. Superselective intra-arterial chemotherapy in the primary management of advanced intra-ocular retinoblastoma: First 4-year experience from a single institution in Turkey. Acta Ophthalmol. 2016;94(7):e644- 51. [Link] [DOI:10.1111/aos.13077]
36. Shields CL, Bianciotto CG, Jabbour P, Ramasubramanian A, Lally SE, Griffin GC, et al. Intra-arterial chemotherapy for retinoblastoma: Report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds. Arch Ophthalmol. 2011;129(11):1399-406. [Link] [DOI:10.1001/archophthalmol.2011.150]
37. Shields CL, Bianciotto CG, Jabbour P, Griffin GC, Ramasubramanian A, Rosenwasser R, et al. Intra-arterial chemotherapy for retinoblastoma: Report No. 2, treatment complications. Arch Ophthalmol. 2011;129(11):1407-15. [Link] [DOI:10.1001/archophthalmol.2011.151]
38. Abramson DH, Fabius AWM, Francis JH, Marr BP, Dunkel IJ, Brodie SE, et al. Ophthalmic artery chemosurgery for eyes with advanced retinoblastoma. Ophthalmic Genet. 2017;38(1):16-21. [Link] [DOI:10.1080/13816810.2016.1244695]
39. Munier FL, Mosimann P, Puccinelli F, Gaillard MC, Stathopoulos C, Houghton S, et al. First-line intra-arterial versus intravenous chemotherapy in unilateral sporadic group D retinoblastoma: Evidence of better visual outcomes, ocular survival and shorter time to success with intra-arterial delivery from retrospective review of 20 years of treatment. Br J Ophthalmol. 2017;101(8):1086-93. [Link] [DOI:10.1136/bjophthalmol-2016-309298]
40. De Francesco S, Galluzzi P, Bracco S, Menicacci F, Motolese E, Hadjistilianou T. Alternated intra-arterial and intravitreal chemotherapy for advanced intraocular retinoblastoma: Preliminary successful results without systemic chemotherapy. Int Ophthalmol. 2015;35(6):887- 95. [Link] [DOI:10.1007/s10792-015-0129-8]
41. Ghassemi F, Shields CL. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch Ophthalmol. 2012;130(10):1268-71. [Link] [DOI:10.1001/archophthalmol.2012.1983]
42. Munier FL, Gaillard MC, Balmer A, Soliman S, Podilsky G, Moulin AP, et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: From prohibition to conditional indications. Br J Ophthalmol. 2012;96(8):1078- 83. [Link] [DOI:10.1136/bjophthalmol-2011-301450]
43. Shields CL, Manjandavida FP, Arepalli S, Kaliki S, Lally SE, Shields JA. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: Preliminary results. JAMA Ophthalmology. 2014;132(3):319-25. [Link] [DOI:10.1001/jamaophthalmol.2013.7666]
44. Tuncer S, Balci O, Tanyildiz B, Kebudi R, Shields CL. Intravitreal lower-Dose (20 µg) melphalan for persistent or recurrent retinoblastoma vitreous seeds. Ophthalmic Surg Lasers Imaging Retina. 2015;46(9):942-8. [Link] [DOI:10.3928/23258160-20151008-07]
45. Ji X, Hua P, Li J, Li J, Zhao J, Zhao P. Intravitreal melphalan for vitreous seeds: Initial experience in China. J Ophthalmol. 2016;2016:4387286. [Link] [DOI:10.1155/2016/4387286]
46. Francis JH, Brodie SE, Marr B, Zabor EC, MondesireCrump I, Abramson DH. Efficacy and toxicity of intravitreous chemotherapy for retinoblastoma: Four-year experience. Ophthalmology. 2017;124(4):488-95. [Link] [DOI:10.1016/j.ophtha.2016.12.015]
47. Jimenez H, Blackman C, Lesser G, Debinski W, Chan M, Sharma S, et al. Use of non-ionizing electromagnetic fields for the treatment of cancer. Front Biosci (Landmark Ed). 2018;23:284-97. [Link] [DOI:10.2741/4591]
48. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol. 2008;26(36):5896-903. [Link] [DOI:10.1200/JCO.2007.15.6794]
49. Beebe SJ, Ford WE, Ren W, Chen X, Schoenbach KH. Non-ionizing radiation with nanosecond pulsed electric fields as a cancer treatment: In vitro studies. Annu Int Conf IEEE Eng Med Biol Soc. 2009;2009:6509-12. [Link] [DOI:10.1109/IEMBS.2009.5333139]
50. Davalos RV, Mir IL, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Engin. 2005;33(2):223-31. [Link] [DOI:10.1007/s10439-005-8981-8]
51. Shirasu N, Nam SO, Kuroki M. Tumor-targeted photodynamic therapy. Anticancer Res. 2013;33(7):2823- 31. [Link]
52. Wei Y, Lu C, Chen Q, Xing D. DNA duplex-based photodynamic molecular beacon for targeted killing of retinoblastoma cell. Investig Ophthalmol Vis Sci. 2016;57(14):6011-9. [Link] [DOI:10.1167/iovs.15-18723]
53. Aerts I, Leuraud P, Blais J, Pouliquen AL, Maillard P, Houdayer C, et al. In vivo efficacy of photodynamic therapy in three new xenograft models of human retinoblastoma. Photodiagn Photodyn Ther. 2010;7(4):275-83. [Link] [DOI:10.1016/j.pdpdt.2010.09.003]
54. Walther J, Schastak S, Dukic-Stefanovic S, Wiedemann P, Neuhaus J, Claudepierre T. Efficient photodynamic therapy on human retinoblastoma cell lines. PloS One. 2014;9(1):e87453. [Link] [DOI:10.1371/journal.pone.0087453]
55. Tsai SR, Hamblin MR. Biological effects and medical applications of infrared radiation. J Photochem Photobiol B Biol. 2017;170:197-207. [Link] [DOI:10.1016/j.jphotobiol.2017.04.014]
56. Anders JJ, Lanzafame RJ, Arany PR. Low-level light/laser therapy versus photobiomodulation therapy. Photomed Laser Surg. 2015;33(4):183-4. [Link] [DOI:10.1089/pho.2015.9848]
57. Passarella S, Karu T. Absorption of monochromatic and narrow band radiation in the visible and near IR by both mitochondrial and non-mitochondrial photoacceptors results in photobiomodulation. J Photochem Photobiol B Biol. 2014;140:344-58. [Link] [DOI:10.1016/j.jphotobiol.2014.07.021]
58. Karu TI. Mitochondrial signaling in mammalian cells activated by red and near-IR radiation. Photochem Photobiol. 2008;84(5):1091-9. [Link] [DOI:10.1111/j.1751-1097.2008.00394.x]
59. de Freitas LF, Hamblin MR. Proposed Mechanisms of Photobiomodulation or Low-Level Light Therapy. IEEE J Sel Top Quantum Electron. 2016;22(3): 7000417. [Link] [DOI:10.1109/JSTQE.2016.2561201]
60. Santana-Blank LA, Rodríguez-Santana E, SantanaRodríguez KE. Photo-infrared pulsed bio-modulation (PIPBM): A novel mechanism for the enhancement of physiologically reparative responses. Photomed Laser Surg. 2005;23(4):416-24. [Link] [DOI:10.1089/pho.2005.23.416]
61. König A, Zöller N, Kippenberger S, Bernd A, Kaufmann R, Layer PG, et al. Non-thermal near-infrared exposure photobiomodulates cellular responses to ionizing radiation in human full thickness skin models. J Photochem Photobiol B Biol. 2018;178:115-23. [Link] [DOI:10.1016/j.jphotobiol.2017.11.003]
62. Künzli BM, Liebl F, Nuhn P, Schuster T, Friess H, Hartel M. Impact of preoperative local water-filtered infrared A irradiation on postoperative wound healing: A randomized patient- and observer-blinded controlled clinical trial. Ann Surg. 2013;258(6):887-94. [Link] [DOI:10.1097/SLA.0000000000000235]
63. Ram R, Uziel O, Eldan O, Fenig E, Beery E, Lichtenberg S, et al. Ionizing radiation up-regulates telomerase activity in cancer cell lines by post-translational mechanism via ras/phosphatidylinositol 3-kinase/Akt pathway. Clin Cancer Res. 2009;15(3):914-23. [Link] [DOI:10.1158/1078-0432.CCR-08-0792]
64. Sun B, Chen M, Hawks CL, Pereira-Smith OM, Hornsby PJ. The minimal set of genetic alterations required for conversion of primary human fibroblasts to cancer cells in the subrenal capsule assay. Neoplasia. 2005;7(6):585-93. [Link] [DOI:10.1593/neo.05172]
65. Akiyama M, Ozaki K, Kawano T, Yamada O, Kawauchi K, Ida H, et al. Telomerase activation as a repair response to radiation-induced DNA damage in Y79 retinoblastoma cells. Cancer Lett. 2013;340(1):82-7. [Link] [DOI:10.1016/j.canlet.2013.07.003]
66. Lim Z, Quah BL. Unilateral retino blastoma in an eye with Peters anomaly. J Am Assoc Pediatr Ophthalmol Strabismu. 2010;14(2):184-6. [Link] [DOI:10.1016/j.jaapos.2010.02.005]
67. Kanber D, Berulava T, Ammerpohl O, Mitter D, Richter J, Siebert R, et al. The human retinoblastoma gene is imprinted. PloS Genet. 2009;5(12):e1000790. [Link] [DOI:10.1371/journal.pgen.1000790]
68. Wilson PF, Nagasawa H, Fitzek MM, Little JB, Bedford JS. G2-phase chromosomal radiosensitivity of primary fibroblasts from hereditary retinoblastoma family members and some apparently normal controls. Radiat Res. 2010;173(1):62-70. [Link] [DOI:10.1667/RR1943.1]
69. Yang Y, Tian S, Brown B, Chen P, Hu H, Xia L, et al. The Rb1 gene inhibits the viability of retinoblastoma cells by regulating homologous recombination. Int J Mol Med. 2013;32(1):137-43. [Link] [DOI:10.3892/ijmm.2013.1374]
70. Knudsen ES, Sexton CR, Mayhew CN. Role of the retinoblastoma tumor suppressor in the maintenance of genome integrity. Curr Mol Med. 2006;6(7):749-57. [Link] [DOI:10.2174/1566524010606070749]
71. Attwooll C, Lazzerini Denchi E, Helin K. The E2F family: Specific functions and overlapping interests. EMBO J. 2004;23(24):4709-16. [Link] [DOI:10.1038/sj.emboj.7600481]
72. Chen J, Zhu F, Weaks RL, Biswas AK, Guo R, Li Y, et al. E2F1 promotes the recruitment of DNA repair factors to sites of DNA double-strand breaks. Cell Cycle. 2011;10(8):1287-94. [Link] [DOI:10.4161/cc.10.8.15341]
73. Guo R, Chen J, Zhu F, Biswas AK, Berton TR, Mitchell DL, et al. E2F1 localizes to sites of UV-induced DNA damage to enhance nucleotide excision repair. J Biol Chem. 2010;285(25):19308-15. [Link] [DOI:10.1074/jbc.M110.121939]